Alvotech (ALVO) Non-Current Assets (2020 - 2026)
Alvotech's (ALVO) quarterly Non-Current Assets came in at $965.2 million in Q1 2026, up 22.71% YoY from $786.6 million in Q1 2025, and up 5.71% on a QoQ basis from $913.1 million in Q4 2025.
Alvotech (ALVO) Non-Current Assets (2020 - 2026) Analysis & Trends
Alvotech (ALVO) has 7 years of Non-Current Assets data on file, last reported at $965.2 million in Q1 2026.
- Quarterly Non-Current Assets rose 22.71% year-over-year to $965.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $965.2 million (up 22.71% YoY) and the FY2025 annual result came in at $913.1 million, up 19.14% from the prior year.
- Non-Current Assets grew to $965.2 million in Q1 2026, from $913.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $977.2 million in Q3 2025 to a low of $535.8 million in Q2 2022.
- A 5-year average of $775.5 million and a median of $775.8 million in 2024 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2023 — Non-Current Assets soared 30.4% — and 2024, when it rose 1.47%.
- Tracing ALVO's Non-Current Assets over 5 years: stood at $597.7 million in 2022, then gained by 26.36% to $755.2 million in 2023, then advanced by 1.47% to $766.4 million in 2024, then rose by 19.14% to $913.1 million in 2025, then gained by 5.71% to $965.2 million in 2026.
- The last three Non-Current Assets figures came in at $965.2 million (Q1 2026), $913.1 million (Q4 2025), and $977.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Alvotech | 1.26 Bn | 1.26 Bn | 5.09 Mn | 965.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 965.19 Mn |
| Dec 31, 2025 | 913.08 Mn |
| Sep 30, 2025 | 977.17 Mn |
| Jun 30, 2025 | 883.29 Mn |
| Mar 31, 2025 | 786.59 Mn |
| Dec 31, 2024 | 766.38 Mn |
| Sep 30, 2024 | 800.34 Mn |
| Jun 30, 2024 | 783.29 Mn |
| Mar 31, 2024 | 768.34 Mn |
| Dec 31, 2023 | 755.25 Mn |
| Jun 30, 2023 | 698.75 Mn |
| Mar 31, 2023 | 626.32 Mn |
| Dec 31, 2022 | 597.71 Mn |
| Jun 30, 2022 | 535.84 Mn |
| Dec 31, 2021 | 478.16 Mn |
| Dec 31, 2020 | 388.26 Mn |